DLL1-responsive PD-L1 + tumor-associated macrophages promote endocrine resistance in breast cancer
Science Translational Medicine · 2025
DOI: 10.1126/scitranslmed.adr6207 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, 2025. Verfasst von Shailesh Singh und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Miller School of Medicine, University of Miami, Miami, FL 33136, USA. Hauptthemen laut MEDLINE: B7-H1 Antigen, Breast Neoplasms, Tumor-Associated Macrophages, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 86 Literaturangaben. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Estrogen receptor–positive (ER + ) luminal breast cancer comprises 75% of patients with breast cancer and presents notable treatment challenges because of endocrine resistance. The effectiveness of immunotherapy in endocrine therapy–resistant luminal breast cancer remains unclear. This limitation is due in part to a lack of immunocompetent preclinical models investigating the comprehensive involvement of immune cells in the tumor microenvironment (TME) in the context of endocrine resistance. In this study, we identified a subtype of immunosuppressive (M2-like) programmed death ligand 1–positive (PD-L1 + ) tumor-associated macrophages (TAMs) critically fostering resistance to tamoxifen (TMX) and fulvestrant (FV) through maintaining cancer stem cell (CSC) activity in new mouse models. These TAMs are recruited by Delta-like ligand 1 (DLL1), a Notch signaling ligand expressed in luminal tumor cells, through the CCR3/CCL7 axis. Combination therapy with anti-DLL1 and anti–PD-L1 antibodies with TMX reduced tumor growth and associated CSCs and reprogrammed the immunosuppressive TME in both preclinical mouse models and patient-derived explants, thus laying the foundation for a future combined immune-endocrine therapy in these patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Miller School of Medicine, University of Miami, Miami, FL 33136, USA.
- Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL 33136, USA.
- Center for Pathobiochemistry and Genetics, Institute of Medical Genetics, Medical University of Vienna, 1090 Vienna, Austria.
- Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
- Department of Pathology and Laboratory Medicine, Miller School of Medicine, University of Miami Health System, Miami, FL 33136, USA.
- Biospecimen Shared Resource, Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL 33136, USA.
ORCID-Profile: Shailesh Singh, Chermakani Panneer Selvam, Marcelo Mendes Götze, Megha Das, Andres Falaschini, Youley Tjendra, Melinda M Boone, Helmut Dolznig, Qing Zhang, Robert Clarke, Rumela Chakrabarti
Förderung
- NCI NIH HHS
Zitieren
APA
Singh, S., Weindorfer, C., Nandi, A., Panneer Selvam, C., Mendes Götze, M., Das, M., Falaschini, A., Tjendra, Y., Boone, M. M., Dolznig, H., Zhang, Q., Clarke, R., Thomas, C., & Chakrabarti, R. (2025). DLL1-responsive PD-L1 + tumor-associated macrophages promote endocrine resistance in breast cancer. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.adr6207
Vancouver
Singh S, Weindorfer C, Nandi A, Panneer Selvam C, Mendes Götze M, Das M, et al. DLL1-responsive PD-L1 + tumor-associated macrophages promote endocrine resistance in breast cancer. Science Translational Medicine. 2025. doi:10.1126/scitranslmed.adr6207
BibTeX
@article{Singh2025,
author = {Singh, Shailesh and Weindorfer, Claudia and Nandi, Ajeya and Panneer Selvam, Chermakani and Mendes Götze, Marcelo and Das, Megha and Falaschini, Andres and Tjendra, Youley and Boone, Melinda M and Dolznig, Helmut and Zhang, Qing and Clarke, Robert and Thomas, Christoforos and Chakrabarti, Rumela},
title = {DLL1-responsive PD-L1 + tumor-associated macrophages promote endocrine resistance in breast cancer},
journal = {Science Translational Medicine},
year = {2025},
doi = {10.1126/scitranslmed.adr6207}
}
EUVIMED